NCT04393350View on ClinicalTrials.gov

Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 22, 2020

Primary Completion Date

September 13, 2024

Study Completion Date

January 16, 2026

Conditions
Kidney CancerStage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8
Interventions
DRUG

Lenvatinib

Given PO

DRUG

Lenvatinib Mesylate

Given PO

BIOLOGICAL

Pembrolizumab

Given IV

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Emory University

OTHER